Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026. - Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance.
From Ionis Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026.
- Tryngolza (FCS) product sales guidance remains $100M-$110M for 2026, with strong Q1 demand suggesting growth momentum.
- SHTG launch (olezarsen) planned for mid-2026 with $100M-$110M revenue estimate; broader patient access and payer coverage expected to expand in 2027, driving further growth.
- Peak revenue for Tryngolza and SHTG combined projected at $3B+, up from prior $2B estimate due to updated pricing and payer research.
- Collaborative revenues expected to rise, with total 2026 revenue guidance raised to $875M-$900M, including commercial and R&D milestones.
2 more points from Ionis Pharmaceuticals, Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Ionis Pharmaceuticals, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ionis is making continued strategic investments to maximize the value of commercial medicines and pipeline.
- Operating expenses are increasing primarily due to commercial investments supporting Tryngolza and DAWNZERA.
- Investments also support launch readiness activities for olezarsen (SHTG) and zilginersen (Alexander’s disease).
- Financial discipline is emphasized, with a low-teen percentage increase in operating expenses compared to last year.
- Resources are being redeployed toward late-stage pipeline drugs fueling the next phase of growth.
2 more points from Ionis Pharmaceuticals, Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Ionis Pharmaceuticals, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Demand for Tryngolza (for FCS) is very strong, with Q1 2026 being the best quarter to date in terms of patient starts and scripts.
- DAWNZERA is experiencing strong early market uptake with increasing prescriptions from both new patients and switches from existing prophylactic therapies.
- For DAWNZERA in 2026, guidance is $110 million to $120 million, reflecting steady order growth driven by switches.
- Olezarsen (for severe hypertriglyceridemia, SHTG) launch expected in mid-2026 with an initial revenue guidance of $100 million to $110 million, growing steadily over time as more patients are identified.
- Priority review for olezarsen with a PDUFA date of June 30, 2026, supports anticipated early demand buildup.
2 more points from Ionis Pharmaceuticals, Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Arthneeti Pro · Annual
Ionis Pharmaceuticals, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ionis Pharmaceuticals, Inc. Q2 FY26 results?
- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026. - Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance.
What is Ionis Pharmaceuticals, Inc. share price analysis?
Ionis Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -122.3 with a market cap of $12,780. Investors should review the full earnings analysis for detailed insights.
Is Ionis Pharmaceuticals, Inc. planning capital expenditure?
- Ionis is making continued strategic investments to maximize the value of commercial medicines and pipeline.
Keep Ionis Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.